跳至主要内容
临床试验/CTRI/2025/06/088308
CTRI/2025/06/088308尚未招募不适用

Assessment of Early Seroconversion by Accelerated Hepatitis B Vaccination in advanced CKD patients- A Randomised Control Study

Dr Nandhini Devi1 个研究点 分布在 1 个国家目标入组 130 人开始时间: 2025年6月15日最近更新:

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
130
试验地点
1
主要终点
The primary outcome of the study was the seroconversion rate at 12 weeks after the first dose of vaccination.

研究概览

简要总结

The study aims to assess the early seroconversion of accelerated Hepatitis B vaccination compared to the standard vaccination regimen in patients with advanced CKD.

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 99.00 Year(s)(—)
性别
All

入选标准

  • 1.Patients aged 18 years and above.
  • 2.Patients with advanced CKD with eGFR less than 15 ml/min per 1.73m
  • 3.Patients not vaccinated with Hepatitis B vaccine earlier.

排除标准

  • 1.Patients with a history of HBV infection.
  • 2.Patients positive for HBsAg. 3.Patients positive for HIV.
  • 4.Recent H/O intake of immunosuppressive drugs.
  • 5.History of allergic adverse effects to other vaccines.

结局指标

主要结局

The primary outcome of the study was the seroconversion rate at 12 weeks after the first dose of vaccination.

时间窗: The primary outcome of the study was the seroconversion rate at 12 weeks after the first dose of vaccination.

次要结局

未报告次要终点

研究者

发起方
Dr Nandhini Devi
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Dr Nandhini Devi R

Stanley Medical College

研究点 (1)

Loading locations...

相似试验